Rejigged deal gives Schering-Plough Japan taribavirin option
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals International has granted Schering-Plough an exclusive option to acquire sole development and commercialisation rights in Japan to its antiviral candidate taribavirin.